Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ARQT vs PVLA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ARQT Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–2 Matrix Metrics)

ARQT Overall Winner 6-Pillar Tally: ARQT 5 – 0 PVLA (1 Tie) Matrix Metrics: ARQT 8 – 2 PVLA

As of Nov 16, 2026, Arcutis Biotherapeutics, Inc. (ARQT) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ARQT carries a Unified Composite Score of 64.4/100 (BUY) at $27.19 (25.8x Forward P/E, 6.9% operating margin), whereas PVLA carries 48.9/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: ARQT trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 45.0); meanwhile PVLA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ARQT vs PVLA
ARQT NASDAQ Head-to-Head Winner
Arcutis Biotherapeutics, Inc. Common Stock
Pharmaceutical Preparations
$27.19
-3.79% 1D
Market Cap $3.5B
TTM Revenue $509M
Forward P/E 25.8x
Beta / 30D Vol 1.76β · 87% Vol
Unified Composite Score
64.4 / 100 BUY
Tech 59.0 Fund 59.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.0 · SMA20: $30.09 · SMA50: $27.60
PVLA NASDAQ
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap $2.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.66β · 75% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 38.0 Fund 52.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.0%) with fading momentum, RSI 47
RSI-14: 47.4 · SMA20: $147.90 · SMA50: $143.31

6-Pillar Scorecard Institutional Category Breakdown (ARQT 5 – 0 PVLA)

Columns: Metric · ARQT · PVLA
1. Valuation Multiples ARQT
Forward P/E 25.8x N/M
Trailing P/E 125.1x N/M
PEG Ratio N/M N/M
EV / Revenue 7.0x N/M
2. Growth & Scale ARQT
Revenue Growth (YoY) +45.1% +0.0%
Earnings Growth (YoY) +3.3% +0.0%
TTM Revenue (USD) $509M N/A
Market Cap $3.5B $2.2B
3. Profitability & Quality ARQT
Gross Margin 91.2% N/A
Operating Margin 6.9% 0.0%
Net Profit Margin 5.9% 0.0%
Return on Equity (ROE) 14.9% -63.4%
4. Balance Sheet & Cash Flow ARQT
Cash Generation (TTM) $60M -$43M
Cash Flow Margin 11.7% N/A
Net Cash / Leverage $81M Net Debt (0.47x D/E) $193M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 60.7% (7th %ile) 47.9% (2nd %ile)
Put/Call OI Skew N/A 3.82x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral DISTRIBUTION · Distribution
6. R&D & Supply-Chain Moat ARQT
OpEx & R&D Intensity 84.3% of Rev ($429M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ARQT (8) vs PVLA (2)
Institutional Metric ARQT PVLA Criterion Row Edge
Market Capitalization
Scale
$3.5B $2.2B Larger Scale ARQT
Trailing P/E Ratio
Valuation
125.1x N/M Lower Multiple ARQT
Forward P/E Ratio
Valuation
25.8x N/M Lower Multiple ARQT
Revenue Growth (YoY)
Growth
+45.1% +0.0% Higher Growth ARQT
Operating Margin (TTM)
Profitability
6.9% 0.0% Higher Margin ARQT
Net Profit Margin
Profitability
5.9% 0.0% Higher Margin ARQT
Return on Equity (ROE)
Capital Efficiency
14.9% -63.4% Higher ROE ARQT
52-Week Range Position
Momentum
51% ($19–$35) 68% ($72–$180) Stronger Trend PVLA
Beta / 30D Volatility
Risk Regime
1.76β · 87% Vol 1.66β · 75% Vol Lower Realized Risk PVLA
Unified Institutional Score
Composite Signal
64.4 / 100 (BUY) 48.9 / 100 (HOLD) Higher Composite ARQT
Trailing 12M Revenue (USD)
Operating Scale
$509M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
91.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.0x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$60M ($81M Net Debt (0.47x D/E)) -$43M ($193M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PVLA +26.22 pp
ARQT: -5.66% · PVLA: +20.56%
3M Horizon ARQT +6.03 pp
ARQT: +2.45% · PVLA: -3.58%
6M Horizon PVLA +2.31 pp
ARQT: +35.75% · PVLA: +38.06%
1Y Horizon PVLA +61.22 pp
ARQT: +18.94% · PVLA: +80.16%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ARQT Revenue PVLA Revenue ARQT Op. Margin PVLA Op. Margin Margin Leader
FY2018 N/A $30M N/A -113.1% PVLA
FY2019 N/A $40M N/A -62.2% PVLA
FY2020 N/A $30M N/A -115.7% PVLA
FY2021 N/A $30M N/A -165.0% PVLA
FY2022 $0M $30M -8183.0% -167.8% PVLA
FY2023 $60M $40M -404.5% -27.7% PVLA
FY2024 $200M N/A -65.3% N/A ARQT
FY2025 $380M N/A -3.3% N/A ARQT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ARQT CONSOLIDATION
91d in phase · OBV ACCUMULATION
Current IV 60.7%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact ARQT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PVLA CONSOLIDATION
70d in phase · OBV DISTRIBUTION
Current IV 47.9%
IV Percentile 2nd %ile
Put/Call OI Skew 3.82x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ARQT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.5B market capitalization and 6.9% operating margin.
OpEx & R&D Reinvestment 84.3% of Rev ($429M)
90D Engineering Disclosures 0 Published
PVLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ARQT vs PVLA Key Questions & Quantitative Answers

As of Nov 16, 2026, Arcutis Biotherapeutics, Inc. (ARQT) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ARQT carries a Unified Composite Score of 64.4/100 (BUY) at $27.19 (25.8x Forward P/E, 6.9% operating margin), whereas PVLA carries 48.9/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: ARQT trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 45.0); meanwhile PVLA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 47.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ARQT leads the Growth & Scale pillar: ARQT posts +45.1% YoY revenue growth and +3.3% YoY earnings growth on $509M TTM revenue (91.2% gross margin, 6.9% operating margin), compared with PVLA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ARQT cumulative revenue shifted +533.3% while PVLA shifted +33.3%. In operating R&D and SG&A reinvestment, ARQT deploys 84.3% of Rev ($429M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PVLA.

ARQT screens cheaper on headline valuation multiples. ARQT trades at 25.8x Forward P/E, 125.1x Trailing P/E, N/M PEG, and 7.0x EV/Revenue (11.7% FCF margin), whereas PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARQT (14.9% ROE) versus PVLA (-63.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ARQT carries 60.7% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.76β · 87% Vol realized risk). By comparison, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.